Sanofi-Aventis Could Refocus Development For PARP Inhibitor Iniparib
This article was originally published in The Pink Sheet Daily
Executive Summary
The French pharma is standing by the first-in-class drug, which failed in a Phase III trial in triple-negative breast cancer, saying it conferred a benefit in heavily pretreated patients.
You may also be interested in...
Tesaro’s Niraparib Takes PARP Inhibitor Lead In Ovarian Cancer
Tesaro Inc. announced the launch of a Phase III trial for its PARP inhibitor niraparib in ovarian cancer, while registrational data from three global Phase III studies for anti-emetic rolapitant are due by the end of 2013.
Tesaro’s Niraparib Takes PARP Inhibitor Lead In Ovarian Cancer
Tesaro Inc. announced the launch of a Phase III trial for its PARP inhibitor niraparib in ovarian cancer, while registrational data from three global Phase III studies for anti-emetic rolapitant are due by the end of 2013.
Making Gains Against Triple-Negative Breast Cancer
Researchers reported on new approaches to the knotty problem of triple-negative breast cancer, using genomics to identify ways of targeting the intractable disease with drugs already in the industry pipeline, at the San Antonio Breast Cancer Symposium Dec. 4-8.